Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately held European pharma is looking for a U.S. partner to commercialize the potentially first-in-class PDE4 inhibitor.
You may also be interested in...
FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote
If FDA had accepted Forest's proposed revised indication for Daxas (roflumilast), the chronic obstructive pulmonary disease drug could have yielded a different outcome from the Pulmonary-Allergy Drugs Advisory Committee
FDA Rejection Of Narrowed Indication For Daxas Led To Negative Panel Vote
If FDA had accepted Forest's proposed revised indication for Daxas (roflumilast), the chronic obstructive pulmonary disease drug could have yielded a different outcome from the Pulmonary-Allergy Drugs Advisory Committee
Good Showing For Nycomed's COPD Drug Daxas
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.